Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, Global Research & Development and Technical

Onyx Pharmaceuticals Appoints Dr. Pablo Cagnoni as Executive Vice President, 
Global Research & Development and Technical Operations 
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/15/13 --  Onyx
Pharmaceuticals, Inc. (NASDAQ: ONXX) today announced the appointment
of Pablo J. Cagnoni, M.D., as Executive Vice President, Global
Research & Development and Technical Operations, effective March
2013. In this role, Dr. Cagnoni will be responsible for managing the
Research & Development organization as well as Technical Operations.
He will report to N. Anthony Coles, M.D., Chairman and Chief
Executive Officer of Onyx.  
"Pablo's broad leadership and management skills, combined with his
track record of developing some of the most successful cancer
therapies -- including Tarceva(R), Afinitor(R) and Folotyn(R) -- make
him the ideal person to lead our efforts in the development of
innovative oncology medicines," said Dr. Coles. "He brings
world-class R&D leadership as Onyx delivers on its vision of becoming
a leading global oncology company committed to bringing new therapies
to patients living with cancer." 
"Onyx has recently transformed from a single-product company into a
company with three approved therapies, and has a pipeline that could
potentially help even more patients, providing oncologists with new
treatment options," said Dr. Cagnoni. "I look forward to joining the
team and leading the continued development of Kyprolis(R)
(carfilzomib) for Injection and Nexavar(R) (sorafenib), as well as
the exciting earlier stage pipeline, all focused on some of the most
difficult-to-treat cancers."  
Before joining Onyx, Dr. Cagnoni was Senior Vice President and Global
Head of Clinical Development of Novartis Oncology. He was responsible
for all clinical development, clinical operations, clinical
pharmacology and correlative sciences activities for the oncology
development pipeline. He oversaw the U.S., European and Japanese
regulatory submissions and approvals of Afinitor(R), Tasigna(R),
Signifor(R), Exjade(R), Jakavi(R) and Glivec(R) in various
indications. He was a member of the Portfolio Management Board and
the Oncology Projects Board and was also accountable for ensuring
timely and effective transition of compounds from early to full
Prior to jo
ining Novartis in 2009, Dr. Cagnoni served as Senior Vice
President and Chief Medical Officer at Allos Therapeutics, Inc. where
he led the team that obtained accelerated approval of Folotyn(R) for
the treatment of peripheral T-cell lymphoma. Dr. Cagnoni was
previously Chief Medical Officer and Vice President of Clinical
Research and Medical Affairs at OSI Pharmaceuticals, where he oversaw
all translational and clinical development activities, including the
submission and approval of Tarceva(R) for the treatment of pancreatic
cancer. Before joining OSI Pharmaceuticals, he served as Vice
President and Head of Clinical Development at Allos Therapeutics.
Previous to his industry experience, Dr. Cagnoni was Assistant
Professor of Medicine and Assistant Director Pharmacology Laboratory,
University of Colorado Bone Marrow Transplant Program. Dr. Cagnoni
earned his medical degree from University Buenos Aires School of
Medicine and he completed his fellowship in Hematology and Oncology,
in the Division of Hematology, Department of Medicine at Mount Sinai
Medical Center, New York and a fellowship in Stem Cell
Transplantation at the University of Colorado Health Sciences Center. 
About Onyx Pharmaceuticals, Inc.
 Based in South San Francisco,
California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical
company engaged in the development and commercialization of
innovative therapies for improving the lives of people with cancer.
The company is focused on developing novel medicines that target key
molecular pathways. For more information about Onyx, visit the
company's website at www.onyx.com. 
Forward-Looking Statements
 This news release contains
"forward-looking statements" of Onyx within the meaning of the
federal securities laws. These forward-looking statements include
without limitation, statements regarding the progress and results of
the clinical development, safety, regulatory processes,
commercialization efforts or commercial potential of Kyprolis
(carfilzomib), Nexavar (sorafenib), Stivarga (regorafenib),
oprozomib, or PD-0332991. These statements are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including risks related to the
development and commercialization of pharmaceutical products. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Reference should be made to Onyx's Annual Report on Form 10-K for the
year ended December 31, 2011, filed with the Securities and Exchange
Commission under the heading "Risk Factors" and Onyx's Quarterly
Reports on Form 10-Q for a more detailed description of such factors.
Readers are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date of this
release. Onyx undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events, or
circumstances after the date of this release except as required by
Onyx Investors 
Amy Figueroa 
Senior Director, Investor Relations 
(650) 266-2398  
Onyx Media
Lori Melancon
Senior Director, Corporate Communications
(650) 266-2394 
Press spacebar to pause and continue. Press esc to stop.